amg‑208

AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met (also known as MET or hepatocyte growth factor receptor) with potential antineoplastic activity. It inhibits both ligand-dependent and ligand-independent activation of c-Met by blocking its tyrosine kinase activity, which may result in inhibition of cell growth in tumors that overexpress c-Met. At higher concentrations, AMG 208 also inhibits other kinases such as RON and VEGF receptor 2. The drug has demonstrated antitumor activity in preclinical models and early clinical trials, particularly in prostate cancer. Developed by Amgen for the treatment of various cancers including solid tumors and prostate cancer, it is administered orally[1][3][5][6].

Other names

7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline1002304-34-8